Conditions: Heart Catheterization
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 53
Healthy volunteers: no

Brief summary:
To assess whether two doses of dabigatran etexilate (110 mg twice daily (b.i.d) and 150 mg twice daily (b.i.d)) as compared to unfractionated heparin (UFH), both in addition to a standard dual antiplatelet regimen, provide sufficient anticoagulation in the setting of elective percutaneous coronary intervention (PCI).

Detailed description:

Arms:
arm 1: experimental drug therapy in this indication arm 2: experimental drug therapy in this indication arm 3: standard therapy in this indication as comparator

Interventions: intervention 1: dabigatran 110 mg intervention 2: dabigatran 150 mg intervention 3: unfractionated heparin
Intervention descriptions: intervention 1: comparison of different dabigatran dosages with unfractionated heparin intervention 2: comparison of different dabigatran dosages with unfractionated heparin intervention 3: comparison of different dosages dabigatran with unfractionated heparin

Protocol document: